BACTROBAN NASAL Rx
Generic Name and Formulations:
Mupirocin (as calcium) 2%; oint.
Indications for BACTROBAN NASAL:
Eradication of nasal colonization of methicillin-resistant S. aureus (MRSA) in adult patients and healthcare workers in certain institutional settings during outbreaks of infections with MRSA (see literature).
Apply approximately 0.25g to inside of each nostril twice daily for 5 days. Spread ointment by repeatedly closing and releasing the nostrils for 1 minute after application.
Avoid eyes. Nasal use in high-risk patients: see full labeling regarding autoinfection. Discontinue if sensitization or severe local irritation occurs. Prolonged use may result in superinfection. Pregnancy. Nursing mothers.
Nasal: avoid other concomitant nasal products.
Topical: burning, stinging, pain, itching. Nasal: headache, rhinitis, respiratory disorder, pharyngitis, taste perversion, burning/stinging, cough, pruritus; severe allergic reactions, C. difficile-associated diarrhea.
Oint—22g; Crm—15g, 30g; Nasal (single-use) (1g)—10
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|